Prostate Cancer News and Research

Latest Prostate Cancer News and Research

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

UTHealth researcher receives grant to develop biochemical diagnosis test for Alzheimer's disease

The Alzheimer's Association has awarded a three-year, $200,000 grant to Claudio Soto, Ph.D., professor of neurology at The University of Texas Health Science Center at Houston (UTHealth), to pursue a procedure that could detect pre-symptomatic Alzheimer's disease.

30 Sep 2010

Radical prostatectomy increases survival rate in prostate cancer patients: Study

In the largest, most modern, single-institution study of its kind, Mayo Clinic urologists mined a long-term data registry for survival rates of patients who underwent radical prostatectomy for localized prostate cancer. The findings are being presented at the North Central Section of the American Urological Association's 84th Annual Meeting in Chicago.

30 Sep 2010

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.

30 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

New predictive test to identify aggressive prostate cancer

S. Mark Redwood, M.D., chief of the Department of Urology at Sinai Hospital, is using a state-of-the-art predictive prostate cancer test called Prostate Px+ to better understand the aggressiveness of each individual patient's cancer and how best to treat it.

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

IsoRay reports increase revenue for 2010 fiscal year

IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.

28 Sep 2010

Researchers find radical prostatectomy provides high survival rates

In one of the first studies to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer researchers have found that surgery provides high survival rates.

28 Sep 2010

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone.

28 Sep 2010

LIMK inhibition blocks collective invasion of tumor cells: Researchers

Researchers have shown that LIM kinase, an important regulator of actin cytoskeleton dynamics, plays a key role in cancer metastasis. The study appears online on September 27 in The Journal of Cell Biology www.jcb.org.

28 Sep 2010

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

Clinical Genomics Pty. Ltd (Sydney, Australia) and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan's proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer.

28 Sep 2010

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).

27 Sep 2010

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.

27 Sep 2010

Alzheimer's treatments may prove effective if started in middle-aged people: Study

Memory lapses that occur with normal aging are a source of worry for many who fear Alzheimer's disease. Now a new Mayo Clinic-led study published in the July 16 issue of the New England Journal of Medicine suggests that the carriers of a common genetic risk factor for Alzheimer's disease begin to have memory declines in their mid-50s, far earlier than previously thought.

27 Sep 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

Concerted effort yields significant progress in reducing depression, HIV/AIDS, and osteoporosis in women

A concerted effort to boost research on women's health over the last two decades has lessened the burden of disease and reduced deaths among women due to cardiovascular disease, breast cancer, and cervical cancer, says a new report from the Institute of Medicine. The effort has yielded less but still significant progress in reducing the effects of depression, HIV/AIDS, and osteoporosis on women, added the committee that wrote the report.

24 Sep 2010

Radiotherapy Centers of Georgia hosts motorcycle ride for prostate cancer awareness

Come ride with the thrill of fresh air in your face. This ride supports prostate cancer awareness, one of the leading killers of men in the state of Georgia. According to the American Cancer Society, Georgia ranks 6th in highest estimated deaths caused by prostate cancer; this is a serious concern for the state and for Radiotherapy Centers of Georgia, a center of excellence in treatment for prostate cancer.

24 Sep 2010

NCCN launches series of guidelines on cancer treatment

Patients with cancer and their caregivers have a new resource to help them navigate the maze of treatment options that they often confront. Today at the NCCN Patient Advocacy Summit in Washington D.C., the National Comprehensive Cancer Network launched its new series of NCCN Guidelines for Patients, consumer-friendly translations of the NCCN Clinical Practice Guidelines in Oncology outlining appropriate cancer treatment.

24 Sep 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

AccuPSA test for detecting prostate cancer recurrence

UTHealth researcher receives grant to develop biochemical diagnosis test for Alzheimer's disease

Radical prostatectomy increases survival rate in prostate cancer patients: Study

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

New predictive test to identify aggressive prostate cancer

Researchers discover new diagnostic test for prostate cancer

New disposable, microfluidic PDMS device for identification of advanced breast cancer

IsoRay reports increase revenue for 2010 fiscal year

Researchers find radical prostatectomy provides high survival rates

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

LIMK inhibition blocks collective invasion of tumor cells: Researchers

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

Alzheimer's treatments may prove effective if started in middle-aged people: Study

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Concerted effort yields significant progress in reducing depression, HIV/AIDS, and osteoporosis in women

Radiotherapy Centers of Georgia hosts motorcycle ride for prostate cancer awareness

NCCN launches series of guidelines on cancer treatment

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in